Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
Date:4/9/2008

the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

The principal investigators are Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, and Dr. Geoff Hall of St. James's Hospital in Leeds, U.K.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R) and carboplatin/paclitaxel clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
4. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
5. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
6. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
7. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
8. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
9. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
11. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... Emerging Growth Equities,Ltd. initiates coverage of CombiMatrix Corporation ... an $18.00 price target. CombiMatrix is a life ... genetic,diagnostics that leverage its core CustomArray technology., ... and investment,banking firm that provides high quality distribution, ...
... Product Line Extension Builds on Existing Brand Strength and Pediatric ... ... Focus, PLYMOUTH MEETING, Pa., Aug. 18 /Xinhua-PRNewswire-FirstCall/ ... that the Sunstone (Tangshan) Pharmaceutical Co., Ltd.,("Sunstone"), its wholly-owned subsidiary, ...
... of Trade Alerts on stocks making news today., Investors ... by visiting:, http://www.BeaconEquity.com/m , Today,s Trade Alerts include: Elan ... ), Amgen Inc. (Nasdaq: AMGN ), Genentech Inc. (NYSE: ... Gilead Sciences Inc. (Nasdaq: GILD )., Join the ...
Cached Biology Technology:Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target 2BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 2BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 3BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 4BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD 2BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD 3
(Date:8/22/2014)... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the FASEB Grant Writing Seminar & Practical Exercises Workshop ... in Bethesda, Maryland from August 25-26, 2014. These ... postdoctorates and research scientists from underrepresented groups in the ... This year MARC conferred 11 awards totaling $20,350. ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
(Date:8/22/2014)... study of captive black rhino reproduction in Europe ... of breeding programmes. , Researchers from Chester Zoo, ... Liverpool carried out a six-year study which encompassed ... Dr Katie Edwards led the research as part ... She says: "Although some black rhinoceros breed well ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Hormone analysis helps identify horny rhinos 2
... March 7, 2013 (Bronx, NY) Researchers at ... been awarded a $12 million grant from the National Institutes ... prevent HIV infection in women. "As we move into ... having its greatest impact on women, particularly in sub-Sahara Africa," ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2013 American College of Sports Medicine (ACSM) Northwest Chapter ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... Research Council (BBSRC) has launched a bioscience response to ... that threatens our third most common broadleaf tree (after ... has been awarded to gather an in-depth understanding of ... about some ash trees, natural resistance to attack. Computer ...
Cached Biology News:Einstein receives $12 million grant to develop device for preventing HIV infection 2Einstein receives $12 million grant to develop device for preventing HIV infection 3Bioscience to battle ash dieback 2Bioscience to battle ash dieback 3
Sterile, Cell culture tested...
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
A substrate for all AChE-based EIA kits....
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
Biology Products: